MedTrace Logo

An Open-label Phase II Study of Lorvotuzumab Mertansine

NCT02420873 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-08-28

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if lorvotuzumab mertansine can help to control blood cancers that have the CD56 tumor marker. The safety of this drug will also be studied.

Conditions

Interventions

DRUG

Lorvotuzumab Mertansine (IMGN901)

100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.

Sponsors & Collaborators

  • ImmunoGen, Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Naval Daver, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-12
Primary Completion
2017-06-06
Completion
2017-06-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02420873 on ClinicalTrials.gov